The FDA approval of lifileucel for advanced melanoma marks a major breakthrough in cancer therapy, as highlighted in a recent commentary.
- The FDA approval of lifileucel is a major breakthrough in cancer therapy for advanced melanoma.
- Tumor-infiltrating lymphocyte (TIL) therapy represents a significant advancement in personalized cancer treatment.
- Preclinical studies on TIL therapy began in the 1980s at the National Cancer Institute and were brought to Moffitt Cancer Center in 2003.
- Moffitt has been pivotal in developing and validating TIL therapy, reducing dropout rates during manufacturing by combining it with anti-melanoma agents.
- Moffitt is actively working on the next generation of TIL therapy to treat various solid tumor cancer types and extend lifesaving treatments to a broader range of cancer patients.
Source link
Oncology